Adverse electrocardiographic effects of rituximab infusion in pemphigus patients.
arrhythmia
cardiac
electrocardiography
pemphigus
rituximab
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
02
08
2020
revised:
29
08
2020
accepted:
07
09
2020
pubmed:
12
9
2020
medline:
15
5
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
Pemphigus encompasses a group of chronic autoimmune blistering diseases of the skin and/or mucosa. Rituximab (RTX) has shown promising efficacy for the treatment of pemphigus in the past decade. Considering potential cardiac side effects, this study was conducted to assess the effects of RTX on electrocardiogram (ECG) parameters in pemphigus patients. This observational cross-sectional study was conducted in 80 consecutive patients with pemphigus who were eligible for RTX infusion. The patients' heart rhythm was monitored before, during and after RTX infusion and ECG parameters were compared before and after the infusion. Eighty patients were included in the study. The median age of the patients was 42 years. The mean and maximum heart rate (HR) increased significantly after RTX infusion compared with pre-infusion mean and maximum HR. The mean corrected QT (QTc) interval, premature atrial contraction (PAC), and premature ventricular contraction (PVC) counts increased significantly after RTX infusion (P value: 0.009, 0.004 and 0.007 respectively). According to the results of this study, RTX has potential arrhythmogenic side effects including increased mean and maximum HR, QTc interval, PAC and PVC count. However, these findings are minor and should not prevent eligible patients from receiving RTX infusion.
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14299Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Didona D, Maglie R, Eming R, Hertl M. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019;10:1418.
Liu V, Mackool B. Mycophenolate in dermatology. J Dermatol Treat. 2003;14(4):203-211.
Arin M, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153(3):620-625.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040.
Arai Y, Tadokoro J, Mitani K. Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. Am J Hematol. 2005;78(4):317-318.
Hishikari K, Kuwahara T, Kimura S, Hikita H, Takahashi A, Isobe M. Reversible atrial fibrillation with bradycardia associated with primary cardiac B-cell lymphoma. Intern Med. 2016;55(6):635-638.
Poterucha JT, Westberg M, Nerheim P, Lovell JP. Rituximab-induced polymorphic ventricular tachycardia. Tex Heart Inst J. 2010;37(2):218-220.
Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92(6):1927-1932.
Larsson HP. How is the heart rate regulated in the sinoatrial node? Another piece to the puzzle. J Gen Physiol. 2010;136(3):237-241.
Rubart M, Zipes DP. Mechanisms of sudden cardiac death. J Clin Invest. 2005;115(9):2305-2315.
Schwartz PJ, Periti M, Malliani A. The long QT syndrome. Am Heart J. 1975;89(3):378-390.
Shah SK. QT interval prolongation: Life-threatening consequences of life saving drugs. 2018
Pishgahi M, Dadkhahfar S, Robati RM, et al. Electrocardiographic changes after high-dose corticosteroid pulse therapy in pemphigus patients. J Dermatol Treat. 2018;29(8):802-805.